Friedreich Ataxia clinical trials
13 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
- Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
- A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
- An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
- Clinical Course Of Disease In Participants With FA-CM
- A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
- A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
- Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
- Biomarkers in Friedreich's Ataxia
- Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
- GABA and GSH in FRDA
- A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Friedreich Ataxia” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.